Literature DB >> 24480377

VEGF and Id-1 in pancreatic adenocarcinoma: prognostic significance and impact on angiogenesis.

D Georgiadou1, T N Sergentanis2, S Sakellariou3, G M Filippakis4, F Zagouri5, D Vlachodimitropoulos6, T Psaltopoulou7, A C Lazaris8, E Patsouris9, G C Zografos10.   

Abstract

OBJECTIVES: The significance of vascular endothelial growth factor (VEGF) and inhibitor of differentiation/DNA synthesis (Id-1) in tumor neoangiogenesis and tumor progression in pancreatic ductal adenocarcinoma (PDAC) is still unclear. Given the central role of VEGF in cancer angiogenesis and the inconclusive results on Id-1 expression in PDAC, it is of great interest to investigate whether Id-1 and VEGF expression are associated with angiogenesis and prognosis in PDAC.
METHODS: Paraffin-embedded specimens from 60 consecutive patients with PDAC were immunostained for VEGF, Id-1 and CD34 and staining quantification was assessed by Image analysis system. The correlations among the expression of individual angiogenic factors and microvessel density (MVD), clinicopathologic features and clinical prognosis were analyzed.
RESULTS: Id-1 and VEGF Positive Activity Indices (PAIs) closely correlated with each other. MVD positively correlated with both Id-1 and VEGF expression. More advanced T and N status correlated with more intense expression of Id-1, VEGF and higher MVD. With regard to prognostic significance higher Id-1 PAI (adjusted HR = 1.69, 95%CI: 1.10-2.59, p = 0.017), higher VEGF PAI (adjusted HR = 2.66, 95%CI: 1.09-6.50, p = 0.032), and MVD (adjusted HR = 1.55, 95%CI: 1.27-1.88, p < 0.001) were associated with poorer survival.
CONCLUSIONS: VEGF and Id-1 overexpression were found to be associated with high MVD and emerged as adverse prognostic factors in terms of patient survival in PDAC. The potential of selective anti-angiogenic targeting therapy for pancreatic malignancies should prompt further validation of the present findings in studies encompassing larger samples and more elaborate techniques.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Id-1; Image analysis; MVD; Pancreatic adenocarcinoma; VEGF

Mesh:

Substances:

Year:  2014        PMID: 24480377     DOI: 10.1016/j.ejso.2014.01.004

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  14 in total

1.  microRNA-454 shows anti-angiogenic and anti-metastatic activity in pancreatic ductal adenocarcinoma by targeting LRP6.

Authors:  Yue Fan; Chenye Shi; Tianyu Li; Tiantao Kuang
Journal:  Am J Cancer Res       Date:  2017-01-01       Impact factor: 6.166

2.  Discovery of new therapeutic targets in ovarian cancer through identifying significantly non-mutated genes.

Authors:  Halema Al-Farsi; Iman Al-Azwani; Joel A Malek; Lotfi Chouchane; Arash Rafii; Najeeb M Halabi
Journal:  J Transl Med       Date:  2022-05-26       Impact factor: 8.440

3.  Comparison of the tumor cell secretome and patient sera for an accurate serum-based diagnosis of pancreatic ductal adenocarcinoma.

Authors:  Shakhawan Mustafa; Longqiang Pan; Aseel Marzoq; Malak Fawaz; Laureen Sander; Felix Rückert; Andrea Schrenk; Christina Hartl; Rico Uhler; Adem Yildirim; Oliver Strobel; Thilo Hackert; Nathalia Giese; Markus W Büchler; Jörg D Hoheisel; Mohamed Saiel Saeed Alhamdani
Journal:  Oncotarget       Date:  2017-02-14

4.  Prognostic ability of DNA-binding protein inhibitor ID-1 expression in patients with oral squamous cell carcinoma.

Authors:  Jian Chen; Fan Zhang; Dong Wang; Zhongjun Yang; Shaohua Liu; Zuoqing Dong
Journal:  Oncol Lett       Date:  2020-04-02       Impact factor: 2.967

5.  Fendiline Enhances the Cytotoxic Effects of Therapeutic Agents on PDAC Cells by Inhibiting Tumor-Promoting Signaling Events: A Potential Strategy to Combat PDAC.

Authors:  Marwa Alhothali; Mevin Mathew; Geeta Iyer; Harshani R Lawrence; Shengyu Yang; Srikumar Chellappan; Jaya Padmanabhan
Journal:  Int J Mol Sci       Date:  2019-05-16       Impact factor: 5.923

6.  MicroRNA-100 and microRNA-21 as markers of survival and chemotherapy response in pancreatic ductal adenocarcinoma UICC stage II.

Authors:  Sameer Abdallah Dhayat; Baha Abdeen; Gabriele Köhler; Norbert Senninger; Jörg Haier; Wolf Arif Mardin
Journal:  Clin Epigenetics       Date:  2015-12-23       Impact factor: 6.551

7.  ID1 promotes hepatocellular carcinoma proliferation and confers chemoresistance to oxaliplatin by activating pentose phosphate pathway.

Authors:  Xin Yin; Bei Tang; Jing-Huan Li; Yan Wang; Lan Zhang; Xiao-Ying Xie; Bo-Heng Zhang; Shuang-Jian Qiu; Wei-Zhong Wu; Zheng-Gang Ren
Journal:  J Exp Clin Cancer Res       Date:  2017-11-23

8.  Cyclooxygenase-2 induces angiogenesis in pancreatic cancer mediated by prostaglandin E2.

Authors:  Chuangao Xie; Xuanfu Xu; Xingpeng Wang; Shumei Wei; Liming Shao; Jiamin Chen; Jianting Cai; Litao Jia
Journal:  Oncol Lett       Date:  2018-05-22       Impact factor: 2.967

9.  Prediction of Chlamydia pneumoniae protein localization in host mitochondria and cytoplasm and possible involvements in lung cancer etiology: a computational approach.

Authors:  Aws Alshamsan; Shahanavaj Khan; Ahamad Imran; Ibrahim A Aljuffali; Khalid Alsaleh
Journal:  Saudi Pharm J       Date:  2017-05-31       Impact factor: 4.330

Review 10.  The Redox Role of G6PD in Cell Growth, Cell Death, and Cancer.

Authors:  Hung-Chi Yang; Yi-Hsuan Wu; Wei-Chen Yen; Hui-Ya Liu; Tsong-Long Hwang; Arnold Stern; Daniel Tsun-Yee Chiu
Journal:  Cells       Date:  2019-09-08       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.